Stratification and Treatment in Early Psychosis Study -ASSIST

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age16-50
SponsorUniversity of Oxford

About this trial

The purpose of this trial is:

* To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients. * To confirm the safety of CBD in people with psychosis.

The trial is a randomised, double-blind, placebo-controlled, multi-centre, international, clinical trial. Individuals with a diagnosis of treatment resistant psychosis in their illness who have had a suboptimal or no response to clozapine treatment will be recruited. These patients are randomised to treatment with oral CBD 500mg twice daily, or a matching placebo for 12 weeks, in addition to clozapine, which is standard care treatment for this population. By using a battery of clinical outcome assessments, the trial will assess several optional biomarkers to predict clinical outcomes and response to treatment with CBD. Biomarkers are being assessed as an exploratory outcome measure. Participants will be invited to provide additional blood samples, stool samples, and complete neuroimaging assessments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

16 to 50 years of age (inclusive) who are willing and able to provide written informed consent/assent (country specific requirements apply).

The patient has been treated with clozapine for at least 8 weeks with a clozapine plasma concentration of at least 0.35 mg/L at screening. If a patient has a lower plasma concentration at screening, the patient can enter the trial at a later date once their plasma concentration is above the threshold*.

Within 10 years of first antipsychotic treatment prescribed for psychosis.

The patient meets DSM-5 criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder, as confirmed through the SCID-5-RV. The patient does not meet modified Andreasen et al (2005) criteria for symptomatic remission cross-sectionally (time requirement does not apply), i.e., a severity rating score of no more than mild (score of </=3) on 8 specified Positive and Negative Syndrome Scale (PANSS) positive and negative symptom items: P1 - Delusions, P2 - Conceptual Disorganization, P3 - Hallucinatory Behaviour, N1 - Blunted Affect, N4 - Passive/Apathetic Social Withdrawal, N6 - Lack of Spontaneity and Flow of Conversation, G5 - Mannerisms and Posturing, G9 - Unusual Thought Content.

Disqualifiers

Current treatment with sodium valproate, valproate semisodium, or clobazam. In cases of current use of these medicines, participation is only permitted if they can and will be discontinued or switched to a suitable alternative medication prior to randomisation.

Hypersensitivity to the active substance, sesame oil, sesame seed or any of the excipients of the trial intervention.

Known hepatic insufficiency and/or transaminase elevations levels exceeding the upper limit of normal 2 times or more and bilirubin greater than 1.5 times the upper limit of normal.

Previous neurosurgery or neurological disorder, including epilepsy, which may affect the trial procedures*.

Trial design

Design model

Parallel

Treatments tested in this trial

  • CBD 100 mg/mL Oral Solution

    Drug

    Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 12 weeks

  • Placeb

    Drug

    5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 12 weeks

Treatment groups

250 Participants
are divided into 2 treatment groups
Group A: Experimental: CannobidiolExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Positive and Negative Syndrome Scale (PANSS) total score

Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to 12 weeks. The minimum value is 1 and the maximum value is 7 for each item of the scale. 1. A patient meets remission criteria if none of the following items score a 4 or higher: P1, P2, P3, N1, N4, N6, G5 and G9. 2. A patient does not meet remission criteria if one or more of these items score a 4 or higher.

Time frame
12 weeks

Secondary outcomes

1

Change in symptoms (sub-scale scores)

Change in scores on the Positive and Negative Syndrome Scale (PANSS) positive, negative and general symptom subscales from baseline to 12 weeks. Total PANSS score: Minimum: 30 (all items scored 1); Maximum: 210 (all items scored 7). Subscale ranges: Positive Scale: 7-49; Negative Scale: 7-49; General Psychopathology Scale: 16-112. Higher PANSS scores = worse outcome; Indicate greater symptom severity. Lower PANSS scores = better outcome; Indicate fewer or less severe symptoms.

Time frame
From baseline to 12 weeks
2

Symptomatic remission

Symptomatic remission after 12 weeks as measured using the Positive and Negative Syndrome Scale (PANSS), defined using Andreasen (2005) remission criteria. Remission is based on the following PANSS: Positive symptoms: P1, P2, P3. Negative symptoms: N1, N4, N6. General psychopathology: G5, G9.Minimum score: 1 (absent); Maximum score: 7 (extreme). Lower scores are better outcome; Higher scores are worse outcome. Andreasen, N. C., Carpenter, W. T., Jr, Kane, J. M., Lasser, R. A., Marder, S. R., \& Weinberger, D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. The American journal of psychiatry, 162(3), 441-449. https://doi.org/10.1176/appi.ajp.162.3.441

Time frame
12 weeks
3

Change in overall clinical impression

Change in overall clinical impression, assessed through Clinical Global Impression of Improvement and Severity (CGI-I/S) scales from baseline to 12 weeks. Clinical Global Impression of Severity (CGI-S) is rated from 1 (normal, not at all ill) to 7 (among the most extremely ill), with lower scores indicating lower illness severity. Clinical Global Impression of Improvement (CGI-I) is rated from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater clinical improvement.

Time frame
From baseline to 12 weeks
4

Change in functioning

Change in functioning, assessed through Social and Occupational Function Scale (SOFAS) from baseline to 12 weeks. Score range 1-100, the higher score means the better function

Time frame
from baseline to 12 weeks

Other outcomes

1

Change in overall patient impression of severity and improvement

Change in overall patient impression, assessed through Patient Global Impression of Improvement and Severity (PGI-I/S) scales from baseline to 12 weeks. The Patient Global Impression of Improvement (PGI-I) is a single question asking the patient to rate how their psychotic symptoms is now compared to the previous study visit on a scale of 1. very much better to 7. very much worse. The lower score is better in symptoms' improvement. The Patient Global Impression of Severity (PGI-S) is a single question asking the patient to rate how their psychotic symptoms is now on a scale of 1. not present to 7. very severe. The lower score is better in symptoms.

Time frame
from baseline to 12 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Oxford

Lead sponsor

Wellcome Trust

Collaborator

Cambridge Cognition Ltd

Collaborator

Cambridgeshire and Peterborough NHS Foundation Trust

Collaborator

Oxford Health NHS Foundation Trust

Collaborator

West London NHS Trust

Collaborator

Charite University, Berlin, Germany

Collaborator

University of Cologne

Collaborator

Ludwig-Maximilians - University of Munich

Collaborator

University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy

Collaborator

The Sheba Fund for Health Services and Research

Collaborator

Shalvata Mental Health Center

Collaborator

Geha Mental Health Center

Collaborator

Amsterdam University Medical Center

Collaborator

National and Kapodistrian University of Athens

Collaborator

Hospital General Universitario Gregorio Marañon

Collaborator

Hospitales Universitarios Virgen del Rocío

Collaborator

University of Campania Luigi Vanvitelli

Collaborator

Psychiatric University Hospital, Zurich

Collaborator

Douglas Hospital Research Centre

Collaborator

This trial is not recruiting at the moment. You can still explore other options: